ImmunityBio (IBRX) Capital Leases (2016 - 2018)

ImmunityBio (IBRX) has 3 years of Capital Leases data on file, last reported at $5.9 million in Q4 2018.

• On a quarterly basis, Capital Leases rose 241.47% year-over-year to $5.9 million in Q4 2018; TTM through Dec 2018 was $5.9 million, a 241.47% increase from a year earlier, with the FY2018 full-year figure at $5.9 million, up 241.47% from the prior year.
• Capital Leases for Q4 2018 stood at $5.9 million, down from $6.1 million in the prior quarter.
• Over the last five years, Capital Leases for IBRX reached as high as $6.3 million in Q2 2018 and fell as low as $1.7 million in Q1 2018.
• Historically, Capital Leases has averaged $3.2 million across 3 years, with a median of $2.0 million in 2016.
• Across the five-year window, Capital Leases dropped 24.1% in 2017 and soared 241.47% in 2018, its largest moves.
• Year by year, Capital Leases stood at $2.0 million in 2016, then slipped by 14.02% to $1.7 million in 2017, then surged by 241.47% to $5.9 million in 2018.
• Per Business Quant data, the three most recent Capital Leases figures were $5.9 million in Q4 2018, $6.1 million in Q3 2018, and $6.3 million in Q2 2018.